Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure

NCT01252810 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Renal Insufficiency
Diabete Mellitus
Congestive Heart Failure

Interventions

DRUG: GE-145

Sponsor

GE Healthcare

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]